<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700244</url>
  </required_header>
  <id_info>
    <org_study_id>LCP004</org_study_id>
    <nct_id>NCT01700244</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Cardiac Pacemaker</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanostim, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanostim, Inc.</source>
  <oversight_info>
    <authority>Czech Republic: SUKL - State Institute for Drug Control</authority>
    <authority>Germany: BfArM - Federal Institute for Drugs and Medical Devices</authority>
    <authority>Netherlands: METC - Medical Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An evaluation of a safety and performance of a new cardiac pacemaker
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complication rate, where a complication is defined as a serious adverse device effect (SADE)</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Atrial Fibrillation With 2 or 3° AV or Bifascicular Bundle Branch (BBB) Block</condition>
  <condition>Normal Sinus Rhythm With 2 or 3° AV or BBB Block</condition>
  <condition>Sinus Bradycardia With Infrequent Pauses or Unexplained Syncope With EP Findings</condition>
  <arm_group>
    <arm_group_label>Pacemaker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker implant</intervention_name>
    <arm_group_label>Pacemaker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have one of the following clinical indications:

               1. Chronic atrial fibrillation  with 2 or 3° AV or bifascicular bundle branch block
                  (BBB block) ; or

               2. Normal sinus rhythm with 2 or 3° AV or BBB block  and a low level of physical
                  activity or short expected lifespan (but at least one year); or

               3. Sinus bradycardia with infrequent pauses or unexplained syncope with EP
                  findings; and

          -  Subject ≥18 years of age;

          -  Subject has life expectancy of at least one year;

          -  Subject is not enrolled in another clinical investigation;

          -  Subject is willing to comply with clinical investigation procedures and agrees to
             return for all required follow-up visits, tests, and exams;

          -  Subject has been informed of the nature of the study, agrees to its provisions and
             has provided written informed consent, approved by the EC;

          -  If female, for 3 months post-operative, subject will actively practice a
             contraception method, or will practice abstinence, or is surgically sterilized, or is
             postmenopausal.

        Exclusion Criteria:

          -  Pacemaker dependent;

          -  Known pacemaker syndrome, have retrograde VA conduction or suffer a drop in arterial
             blood pressure with the onset of ventricular pacing;

          -  Hypersensitivity to &lt; 1 mg of dexamethasone sodium phosphate;

          -  Mechanical tricuspid valve prosthesis;

          -  Pre-existing pulmonary arterial (PA) hypertension  or significant
             physiologically-impairing lung disease;

          -  Pre-existing  pacing or defibrillation leads;

          -  Current implantation of an implantable cardioverter defibrillator (ICD) or cardiac
             resynchronization therapy (CRT);

          -  Presence of implanted vena cava filter;

          -  Presence of implanted leadless cardiac pacemaker;

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Sperzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague 5</city>
        <state>Prague</state>
        <zip>15000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Clinic</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
